We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00567047
Recruitment Status : Completed
First Posted : December 4, 2007
Last Update Posted : March 25, 2009
Information provided by:

December 3, 2007
December 4, 2007
March 25, 2009
July 2007
January 2009   (Final data collection date for primary outcome measure)
• Pharmacokinetic measures [ Time Frame: throughout the study ]
Same as current
Complete list of historical versions of study NCT00567047 on ClinicalTrials.gov Archive Site
• Safety and tolerability measures [ Time Frame: throughout the study ]
Same as current
Not Provided
Not Provided
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate or Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Daily Doses of 50 mg Vildagliptin for 14 Days
This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.
Not Provided
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Type-2 Diabetes
Drug: vildagliptin
Other Name: LAF237
Experimental: 1
Intervention: Drug: vildagliptin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria (general):

  • Men and women (age 18 to 85 years)
  • Participants must be nonfertile or using a medically approved birth control method. Additional information regarding this requirement available at screening
  • Body mass index (BMI) ≤42 kg/m2 (inclusive)

Inclusion Criteria (for renal insufficient patients):

  • Patients with mild, moderate, or severe kidney impairment. Please consult with participating physicians regarding the definitions of these levels of severity.
  • Patients with diabetes must be treated with standard anti-diabetic therapy (diet and exercise, stable dose of sulfonylurea, insulin, or metiglinides) and agree to continue for the study duration

Inclusion Criteria (for healthy subjects):

  • No current significant medical conditions as determined by history and physical.
  • Serum creatinine with a calculated creatinine clearance (CrCl) of >80 ml/min.
  • Matched to renal impaired patients in the study by age (±5 years), sex and weight (±10% BMI)
  • Vital signs guided by the following ranges:

oral body temperature between 35.0-37.2 °C systolic blood pressure, 100-140 mm Hg diastolic blood pressure, 60-110 mm Hg pulse rate, 45-90 bpm

Exclusion criteria:

  • Pregnant or lactating female.
  • A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, acute metabolic diabetic complications (eg, ketoacidosis or hyperosmolar state (coma))
  • Subjects that have been enrolled in previous vildagliptin studies or other DPP
  • 4 inhibitor studies within six months
  • History of renal transplant or immunosuppressant therapy
  • Acute infections which may affect blood glucose control or other medical condition that may interfere with the interpretation of efficacy and safety data during the study
  • Any pre-existing or history of diabetic ulcer
  • Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery or percutaneous coronary intervention, unstable angina or stroke
  • Any of the following electrocardiogram (ECG) abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation, second degree atrioventricular (AV) block (Mobitz 1 and 2), third degree AV block, prolonged QTc (>500 ms)
  • Malignancy including leukemia and lymphoma within the last 5 years.
  • Liver disease such as cirrhosis or positive hepatitis B and C.
  • Any alcohol related hepatic disease.
  • Patients undergoing any method of dialysis
  • Use of some concomitant medications
  • Significant laboratory abnormalities as specified in the protocol
  • History of active substance abuse (including alcohol) within the past 2 years.
  • Smokers (i.e., 10 or more cigarettes per day)
  • History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures

Other protocol-defined inclusion/exclusion criteria may apply

Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Germany,   United States
Not Provided
Not Provided
Not Provided
Principal Investigator: Novartis Novartis investigative site
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP